Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors

Author(s): Olga Panagiotopoulou, Scott T. Chiesa, Dimitrios Tousoulis, Marietta Charakida*.

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 27 , 2020

Become EABM
Become Reviewer


Genetic, experimental and clinical studies have consistently confirmed that inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) can result in significant lowering of LDL-C and two fully human PCSK9 monoclonal antibodies have received regulatory approval for use in highrisk patients. Co-administration of PCSK9 with statins has resulted in extremely low LDL-C levels with excellent short-term safety profiles. While results from Phase III clinical trials provided significant evidence about the role of PCSK9 inhibitors in reducing cardiovascular event rates, their impact on mortality remains less clear. PCSK9 inhibitor therapy can be considered for high-risk patients who are likely to experience significant cardiovascular risk reduction.

Keywords: PCSK9, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), alirocumab, evolocumab, LDLcholesterol, monoclonal antibodies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [4494 - 4521]
Pages: 28
DOI: 10.2174/0929867326666190827151012
Price: $95

Article Metrics

PDF: 12